Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Catalyst PharmaceuticalsCPRX +0.02%70 EV-to-EBITDA is 10.14 as of Sep. 02, 2026, which is 4% above its 10-year median of 9.71. GuruFocus rates CPRX with a GF Score™ of 70/100 and a GF Value™ of $25.01 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 401 Biotechnology companies, Catalyst Pharmaceuticals ranks better than 57.61% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Catalyst Pharmaceuticals's enterprise value is $3,101.7 Mil.
Catalyst Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $305.8 Mil. Therefore, Catalyst Pharmaceuticals's EV-to-EBITDA for today is 10.14.
The historical rank and industry rank for Catalyst Pharmaceuticals's EV-to-EBITDA or its related term are showing as below:
CPRX'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -49.83 Med: 9.71 Max: 56.99
Current: 10.14
During the past 13 years, the highest EV-to-EBITDA of Catalyst Pharmaceuticals was 56.99. The lowest was -49.83. And the median was 9.71.
CPRX's EV-to-EBITDA is ranked better than 57.61% of 401
companies
in the Biotechnology industry
Industry Median: 13.99
vs CPRX: 10.14
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Catalyst Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Catalyst Pharmaceuticals's share price for today is $31.49.
Catalyst Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.740.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Catalyst Pharmaceuticals's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Catalyst Pharmaceuticals EV-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Catalyst Pharmaceuticals's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Catalyst Pharmaceuticals's EV-to-EBITDA falls into.
Catalyst Pharmaceuticals's current Enterprise Value is $3,101.7 Mil.
Catalyst Pharmaceuticals's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $305.8 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Catalyst Pharmaceuticals (CPRX) has a EV-to-EBITDA of 10.14 as of Sep. 02, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Catalyst Pharmaceuticals. This is near median its historical median of 9.71. According to the industry distribution chart, Catalyst Pharmaceuticals ranks #170 out of 401 companies in the Biotechnology industry, placing it in the top 42.4%.
Is Catalyst Pharmaceuticals' EV-to-EBITDA too high?
Catalyst Pharmaceuticals' current EV-to-EBITDA of 10.14 is near median its 10-year median of 9.71. The Biotechnology industry median EV-to-EBITDA is 13.99. Catalyst Pharmaceuticals' value of 10.14 is 27.5% below this industry median. Based on the distribution chart, Catalyst Pharmaceuticals ranks #170 out of 401 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Catalyst Pharmaceuticals has a GF Score™ of 70/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Catalyst Pharmaceuticals' EV-to-EBITDA compare to PBLS and ELVN?
According to the Biotechnology industry distribution chart, Catalyst Pharmaceuticals ranks #170 out of 401 companies for EV-to-EBITDA. This puts Catalyst Pharmaceuticals in the upper half of its industry. The industry median EV-to-EBITDA is 13.99. Catalyst Pharmaceuticals' value of 10.14 is 27.5% below this benchmark. While the company's 10-year median is 9.71 vs. the industry median of 13.99, Catalyst Pharmaceuticals has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Biotechnology company?
The median EV-to-EBITDA among Biotechnology companies is 13.99, based on 401 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Catalyst Pharmaceuticals's current EV-to-EBITDA of 10.14 is 27.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Catalyst Pharmaceuticals. For the Biotechnology industry, the median EV-to-EBITDA is 13.99 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Catalyst Pharmaceuticals's current EV-to-EBITDA is 10.14, which is near median its own 10-year median of 9.71. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Catalyst Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals (CPRX) is currently considered Modestly Overvalued. The stock's GF Value™ is $25.01, compared to a current price of $31.49 — trading 25.9% above its estimated fair value. The current EV-to-EBITDA is 10.14, which is near median its 10-year median of 9.71 and 27.5% below the Biotechnology industry median of 13.99. Catalyst Pharmaceuticals' overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Catalyst Pharmaceuticals (CPRX), the current EV-to-EBITDA is 10.14 as of Sep. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Catalyst Pharmaceuticals (CPRX) Overvalued in 2026?
Based on GuruFocus' analysis, Catalyst Pharmaceuticals stock appears to be overvalued.
The current stock price of $31.49 is trading 25.9% above its estimated GF Value™ of $25.01.
GuruFocus considers Catalyst Pharmaceuticals to be Modestly Overvalued.
Key valuation signals for CPRX:
EV-to-EBITDA: 10.14 (near median its 10-year median of 9.71)
GF Value™: $25.01 vs. price of $31.49 (25.9% above fair value)
Industry Position: 27.5% below the Biotechnology median (#170 of 401)
No single metric tells the full story. See the CPRX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Catalyst Pharmaceuticals Inc is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare and difficult to treat diseases. The Company sells three commercial stage drug products, FIRDAPSE (amifampridine), AGAMREE (vamorolone), and FYCOMPA (perampanel). The Company is currently seeking to further expand its product portfolio, with a focus on acquiring the rights to immediately and near-term accretive assets to treat rare (orphan) diseases across therapeutic areas, including clinical-stage opportunities with established proof of concept.
70GF Score
Get the complete analysis for CPRX
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CPRX has been successfully added to your 
